MedTrace Logo

Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer

NCT06600906 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2025-11-12

No results posted yet for this study

Summary

This study evaluates an investigational scan called hyperpolarized carbon-13 pyruvate magnetic resonance imaging (MRI) in assessing treatment response in patients with pancreatic ductal carcinoma (PDA) that has spread to nearby tissue or lymph nodes (locally advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). MRI is a standard scan that helps doctors see tumors, organs, tissue, and bone. Standard contrast agents (e.g., gadolinium) are sometimes used to help make the scan images brighter, or easier to see. Hyperpolarized carbon-13 pyruvate is an experimental contrast agent that is different from standard MRI contrast in that it provides information on how a tumor processes nutrients. Hyperpolarized carbon-13 pyruvate MRI scans may work better than MRI with standard contrast agents in predicting how PDA tumors respond to treatment.

Conditions

Interventions

DRUG

Hyperpolarized 13C-Pyruvate

Given intravenously (IV)

PROCEDURE

Computed tomography (CT)

Undergo CT imaging

PROCEDURE

Magnetic Resonance Imaging (MRI)

Undergo MRI imaging

Sponsors & Collaborators

Principal Investigators

  • Zhen Wang, MD · University of California, San Francisco

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-01
Primary Completion
2030-08-01
Completion
2032-09-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06600906 on ClinicalTrials.gov